Respiratory Therapeutics Market by Drug Type (Antifibrotic Agents, Antihistamines, Bronchodilators, Combination of LABA/ICS, Immunosuppressants, Leukotriene Antagonists, Mast Cell Stabilizers, Tyrosine Kinase Inhibitors, Others), Disease Type or Application (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Cystic Fibrosis, Others) and Forecast 2017-2021

Respiratory Therapeutics Market by Drug Type (Antifibrotic Agents, Antihistamines, Bronchodilators, Combination of LABA/ICS, Immunosuppressants, Leukotriene Antagonists, Mast Cell Stabilizers, Tyrosine Kinase Inhibitors, Others), Disease Type or Application (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Cystic Fibrosis, Others) and Forecast 2017-2021

Respiratory therapeutics mostly include inhaling medications, although enteral, parenteral, transdermal, or topical routes of administration may be used for some drugs for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma and more. Antimicrobial medications used for the treatment of breathing infections include tobramycin (TOBI), ribavirin (Virazole), pentamidine (Nebupent). IV antibiotics can be used for the treatment of acute cases of infection, such as bacterial pneumonia or bacterial bronchitis. These are used in an intravenous manner for curing the respiratory problems of patients. Corticosteroids such as Budesonide (Pulmicort Respules are designed to reduce swelling in the airways. Bronchodilator medications such as Metaproterenol (Alupent) and ipratropium (Atrovent) are used in order to open and relax the air passages. Short-acting beta agonists such as Levalbuterol HCl (Xopenex) and albuterol sulfate (AccuNeb) are actually a type of bronchodilators. Long-acting beta agonists such as Formoterol (Perforomist) and arformoterol (Brovana).  Racemic epinephrine is used for treating croup, severe attacks of asthma and other emergency respiratory cases. Mucolytics such as Dornase alfa (Pulmozyme) and acetylcysteine (Mucomyst) are used for thinning, loosening and clearing out secretions of mucus from lungs. Combination drugs such as Albuterol (DuoNeb) / ipratropium are useful for alleviating respiratory symptoms.

The global respiratory therapeutics market segmentation is based on drug type (antifibrotic agents, antihistamines, bronchodilators, combination of LABA/ICS, immunosuppressants, leukotriene antagonists, mast cell stabilizers, tyrosine kinase inhibitors, others), and disease type or application (allergic rhinitis, asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and cystic fibrosis, others).

The global respiratory therapeutics market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global respiratory therapeutics market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World. The global respiratory therapeutics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global respiratory therapeutics market and profiled in this report include Adams Respiratory Therapeutics, Inc., AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, and Respiratory Therapeutics Group, LLC.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Respiratory Therapeutics Market

1. Drug Type
1.1. Antifibrotic Agents
1.2. Antihistamines
1.3. Bronchodilators
1.4. Combination of LABA/ICS
1.5. Immunosuppressants
1.6. Leukotriene Antagonists
1.7. Mast Cell Stabilizers
1.8. Tyrosine Kinase Inhibitors
1.9. Others

2. Disease Type (Application)
2.1. Allergic Rhinitis
2.2. Asthma
2.3. Chronic Obstructive Pulmonary Disease (COPD)
2.4. Idiopathic Pulmonary Fibrosis (IPF) and Cystic Fibrosis
2.5. Others

3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.3. Latin America (Brazil, Mexico, Rest of LA)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World (Middle East & Africa)

4. Company Profiles
4.1. Adams Respiratory Therapeutics, Inc.
4.2. AstraZeneca
4.3. Boehringer Ingelheim
4.4. F. Hoffmann-La Roche
4.5. GlaxoSmithKline
4.6. Merck
4.7. Novartis
4.8. Respiratory Therapeutics Group, LLC

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*

EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish